AVITA Medical, Inc.
Get $10 bonus on your first $100 deposit for RCEL
Get $10 bonus on your first $100 deposit for RCEL
AVITA Medical, Inc. (RCEL) Stock Competitors & Peer Comparison
See (RCEL) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RCEL | $4.54 | +10.73% | 112.8M | -2.61 | -$1.74 | N/A |
| ABT | $102.72 | -0.81% | 178.5B | 27.17 | $3.78 | +2.33% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| SYK | $339.14 | -0.26% | 129.8B | 40.37 | $8.40 | +1.02% |
| MDT | $87.91 | -0.83% | 112.9B | 24.56 | $3.58 | +3.22% |
| BSX | $61.28 | -2.05% | 91.1B | 31.58 | $1.94 | N/A |
| EW | $79.15 | -3.13% | 46B | 43.71 | $1.81 | N/A |
| BRKRP | $299.91 | -0.76% | 45.7B | N/A | N/A | +0.53% |
| PHG | $28.13 | +0.29% | 27B | 26.29 | $1.07 | +3.14% |
| DXCM | $65.68 | -0.18% | 25.6B | 31.43 | $2.09 | N/A |
Stock Comparison
RCEL vs ABT Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, ABT has a market cap of 178.5B. Regarding current trading prices, RCEL is priced at $4.54, while ABT trades at $102.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas ABT's P/E ratio is 27.17. In terms of profitability, RCEL's ROE is +4.77%, compared to ABT's ROE of +0.13%. Regarding short-term risk, RCEL is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check ABT's competition here
RCEL vs BSX-PA Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, RCEL is priced at $4.54, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, RCEL's ROE is +4.77%, compared to BSX-PA's ROE of +0.13%. Regarding short-term risk, RCEL is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check BSX-PA's competition here
RCEL vs SYK Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, SYK has a market cap of 129.8B. Regarding current trading prices, RCEL is priced at $4.54, while SYK trades at $339.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas SYK's P/E ratio is 40.37. In terms of profitability, RCEL's ROE is +4.77%, compared to SYK's ROE of +0.15%. Regarding short-term risk, RCEL is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check SYK's competition here
RCEL vs MDT Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, MDT has a market cap of 112.9B. Regarding current trading prices, RCEL is priced at $4.54, while MDT trades at $87.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas MDT's P/E ratio is 24.56. In terms of profitability, RCEL's ROE is +4.77%, compared to MDT's ROE of +0.10%. Regarding short-term risk, RCEL is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check MDT's competition here
RCEL vs BSX Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, BSX has a market cap of 91.1B. Regarding current trading prices, RCEL is priced at $4.54, while BSX trades at $61.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas BSX's P/E ratio is 31.58. In terms of profitability, RCEL's ROE is +4.77%, compared to BSX's ROE of +0.13%. Regarding short-term risk, RCEL is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check BSX's competition here
RCEL vs EW Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, EW has a market cap of 46B. Regarding current trading prices, RCEL is priced at $4.54, while EW trades at $79.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas EW's P/E ratio is 43.71. In terms of profitability, RCEL's ROE is +4.77%, compared to EW's ROE of +0.10%. Regarding short-term risk, RCEL is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check EW's competition here
RCEL vs BRKRP Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, BRKRP has a market cap of 45.7B. Regarding current trading prices, RCEL is priced at $4.54, while BRKRP trades at $299.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas BRKRP's P/E ratio is N/A. In terms of profitability, RCEL's ROE is +4.77%, compared to BRKRP's ROE of -0.00%. Regarding short-term risk, RCEL is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check BRKRP's competition here
RCEL vs PHG Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, PHG has a market cap of 27B. Regarding current trading prices, RCEL is priced at $4.54, while PHG trades at $28.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas PHG's P/E ratio is 26.29. In terms of profitability, RCEL's ROE is +4.77%, compared to PHG's ROE of +0.08%. Regarding short-term risk, RCEL is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check PHG's competition here
RCEL vs DXCM Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, DXCM has a market cap of 25.6B. Regarding current trading prices, RCEL is priced at $4.54, while DXCM trades at $65.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas DXCM's P/E ratio is 31.43. In terms of profitability, RCEL's ROE is +4.77%, compared to DXCM's ROE of +0.32%. Regarding short-term risk, RCEL is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check DXCM's competition here
RCEL vs STE Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, STE has a market cap of 22B. Regarding current trading prices, RCEL is priced at $4.54, while STE trades at $223.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas STE's P/E ratio is 31.21. In terms of profitability, RCEL's ROE is +4.77%, compared to STE's ROE of +0.10%. Regarding short-term risk, RCEL is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check STE's competition here
RCEL vs ZBH Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, ZBH has a market cap of 18.2B. Regarding current trading prices, RCEL is priced at $4.54, while ZBH trades at $93.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas ZBH's P/E ratio is 26.20. In terms of profitability, RCEL's ROE is +4.77%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, RCEL is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check ZBH's competition here
RCEL vs ABMD Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, RCEL is priced at $4.54, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas ABMD's P/E ratio is 65.36. In terms of profitability, RCEL's ROE is +4.77%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, RCEL is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check ABMD's competition here
RCEL vs SNN Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, SNN has a market cap of 14.1B. Regarding current trading prices, RCEL is priced at $4.54, while SNN trades at $33.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas SNN's P/E ratio is 23.17. In terms of profitability, RCEL's ROE is +4.77%, compared to SNN's ROE of +0.12%. Regarding short-term risk, RCEL is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check SNN's competition here
RCEL vs PODD Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, PODD has a market cap of 14B. Regarding current trading prices, RCEL is priced at $4.54, while PODD trades at $199.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas PODD's P/E ratio is 57.47. In terms of profitability, RCEL's ROE is +4.77%, compared to PODD's ROE of +0.17%. Regarding short-term risk, RCEL is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check PODD's competition here
RCEL vs PEN Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, PEN has a market cap of 12.9B. Regarding current trading prices, RCEL is priced at $4.54, while PEN trades at $329.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas PEN's P/E ratio is 72.73. In terms of profitability, RCEL's ROE is +4.77%, compared to PEN's ROE of +0.13%. Regarding short-term risk, RCEL is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check PEN's competition here
RCEL vs SWAV Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, RCEL is priced at $4.54, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas SWAV's P/E ratio is 78.76. In terms of profitability, RCEL's ROE is +4.77%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, RCEL is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check SWAV's competition here
RCEL vs ALGN Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, ALGN has a market cap of 12.5B. Regarding current trading prices, RCEL is priced at $4.54, while ALGN trades at $174.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas ALGN's P/E ratio is 30.84. In terms of profitability, RCEL's ROE is +4.77%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, RCEL is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check ALGN's competition here
RCEL vs GMED Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, GMED has a market cap of 12.4B. Regarding current trading prices, RCEL is priced at $4.54, while GMED trades at $91.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas GMED's P/E ratio is 23.32. In terms of profitability, RCEL's ROE is +4.77%, compared to GMED's ROE of +0.12%. Regarding short-term risk, RCEL is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check GMED's competition here
RCEL vs BIO Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, BIO has a market cap of 7.5B. Regarding current trading prices, RCEL is priced at $4.54, while BIO trades at $277.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas BIO's P/E ratio is 9.96. In terms of profitability, RCEL's ROE is +4.77%, compared to BIO's ROE of +0.11%. Regarding short-term risk, RCEL is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check BIO's competition here
RCEL vs BIO-B Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, BIO-B has a market cap of 7.5B. Regarding current trading prices, RCEL is priced at $4.54, while BIO-B trades at $277.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas BIO-B's P/E ratio is 9.95. In terms of profitability, RCEL's ROE is +4.77%, compared to BIO-B's ROE of +0.11%. Regarding short-term risk, RCEL is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check BIO-B's competition here
RCEL vs GKOS Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, GKOS has a market cap of 6.9B. Regarding current trading prices, RCEL is priced at $4.54, while GKOS trades at $119.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas GKOS's P/E ratio is -35.33. In terms of profitability, RCEL's ROE is +4.77%, compared to GKOS's ROE of -0.25%. Regarding short-term risk, RCEL is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check GKOS's competition here
RCEL vs BRKR Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, BRKR has a market cap of 5.8B. Regarding current trading prices, RCEL is priced at $4.54, while BRKR trades at $37.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas BRKR's P/E ratio is -253.20. In terms of profitability, RCEL's ROE is +4.77%, compared to BRKR's ROE of -0.00%. Regarding short-term risk, RCEL is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check BRKR's competition here
RCEL vs NARI Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, RCEL is priced at $4.54, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas NARI's P/E ratio is -59.24. In terms of profitability, RCEL's ROE is +4.77%, compared to NARI's ROE of -0.00%. Regarding short-term risk, RCEL is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check NARI's competition here
RCEL vs IRTC Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, IRTC has a market cap of 3.8B. Regarding current trading prices, RCEL is priced at $4.54, while IRTC trades at $118.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas IRTC's P/E ratio is -85.01. In terms of profitability, RCEL's ROE is +4.77%, compared to IRTC's ROE of -0.38%. Regarding short-term risk, RCEL is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check IRTC's competition here
RCEL vs TMDX Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, TMDX has a market cap of 3.7B. Regarding current trading prices, RCEL is priced at $4.54, while TMDX trades at $109.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas TMDX's P/E ratio is 22.42. In terms of profitability, RCEL's ROE is +4.77%, compared to TMDX's ROE of +0.54%. Regarding short-term risk, RCEL is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check TMDX's competition here
RCEL vs AXNX Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, RCEL is priced at $4.54, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas AXNX's P/E ratio is -709.80. In terms of profitability, RCEL's ROE is +4.77%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, RCEL is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check AXNX's competition here
RCEL vs LIVN Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, LIVN has a market cap of 3.5B. Regarding current trading prices, RCEL is priced at $4.54, while LIVN trades at $63.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas LIVN's P/E ratio is -14.24. In terms of profitability, RCEL's ROE is +4.77%, compared to LIVN's ROE of -0.21%. Regarding short-term risk, RCEL is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check LIVN's competition here
RCEL vs ITGR Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, ITGR has a market cap of 3B. Regarding current trading prices, RCEL is priced at $4.54, while ITGR trades at $86.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas ITGR's P/E ratio is 29.99. In terms of profitability, RCEL's ROE is +4.77%, compared to ITGR's ROE of +0.06%. Regarding short-term risk, RCEL is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check ITGR's competition here
RCEL vs NUVA Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, RCEL is priced at $4.54, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas NUVA's P/E ratio is 75.00. In terms of profitability, RCEL's ROE is +4.77%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, RCEL is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check NUVA's competition here
RCEL vs ESTA Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, ESTA has a market cap of 1.8B. Regarding current trading prices, RCEL is priced at $4.54, while ESTA trades at $62.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas ESTA's P/E ratio is -36.94. In terms of profitability, RCEL's ROE is +4.77%, compared to ESTA's ROE of -2.02%. Regarding short-term risk, RCEL is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check ESTA's competition here
RCEL vs AORT Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, AORT has a market cap of 1.7B. Regarding current trading prices, RCEL is priced at $4.54, while AORT trades at $36.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas AORT's P/E ratio is 173.90. In terms of profitability, RCEL's ROE is +4.77%, compared to AORT's ROE of +0.02%. Regarding short-term risk, RCEL is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check AORT's competition here
RCEL vs AXGN Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, AXGN has a market cap of 1.7B. Regarding current trading prices, RCEL is priced at $4.54, while AXGN trades at $33.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas AXGN's P/E ratio is -97.12. In terms of profitability, RCEL's ROE is +4.77%, compared to AXGN's ROE of -0.13%. Regarding short-term risk, RCEL is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check AXGN's competition here
RCEL vs ATEC Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, ATEC has a market cap of 1.7B. Regarding current trading prices, RCEL is priced at $4.54, while ATEC trades at $11.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas ATEC's P/E ratio is -11.53. In terms of profitability, RCEL's ROE is +4.77%, compared to ATEC's ROE of -17.60%. Regarding short-term risk, RCEL is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check ATEC's competition here
RCEL vs AHCO Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, AHCO has a market cap of 1.7B. Regarding current trading prices, RCEL is priced at $4.54, while AHCO trades at $12.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas AHCO's P/E ratio is -23.50. In terms of profitability, RCEL's ROE is +4.77%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, RCEL is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check AHCO's competition here
RCEL vs INSP Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, INSP has a market cap of 1.6B. Regarding current trading prices, RCEL is priced at $4.54, while INSP trades at $56.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas INSP's P/E ratio is 11.61. In terms of profitability, RCEL's ROE is +4.77%, compared to INSP's ROE of +0.21%. Regarding short-term risk, RCEL is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for RCEL.Check INSP's competition here
RCEL vs PMI Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, PMI has a market cap of 1.6B. Regarding current trading prices, RCEL is priced at $4.54, while PMI trades at $0.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas PMI's P/E ratio is -1.36. In terms of profitability, RCEL's ROE is +4.77%, compared to PMI's ROE of +2.17%. Regarding short-term risk, RCEL is more volatile compared to PMI. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check PMI's competition here
RCEL vs UFPT Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, UFPT has a market cap of 1.6B. Regarding current trading prices, RCEL is priced at $4.54, while UFPT trades at $203.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas UFPT's P/E ratio is 23.27. In terms of profitability, RCEL's ROE is +4.77%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, RCEL is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check UFPT's competition here
RCEL vs TNDM Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, TNDM has a market cap of 1.3B. Regarding current trading prices, RCEL is priced at $4.54, while TNDM trades at $19.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas TNDM's P/E ratio is -6.47. In terms of profitability, RCEL's ROE is +4.77%, compared to TNDM's ROE of -1.42%. Regarding short-term risk, RCEL is more volatile compared to TNDM. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check TNDM's competition here
RCEL vs PRCT Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, PRCT has a market cap of 1.3B. Regarding current trading prices, RCEL is priced at $4.54, while PRCT trades at $23.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas PRCT's P/E ratio is -13.85. In terms of profitability, RCEL's ROE is +4.77%, compared to PRCT's ROE of -0.25%. Regarding short-term risk, RCEL is more volatile compared to PRCT. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check PRCT's competition here
RCEL vs HSKA Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, RCEL is priced at $4.54, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas HSKA's P/E ratio is -62.49. In terms of profitability, RCEL's ROE is +4.77%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, RCEL is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check HSKA's competition here
RCEL vs IRMD Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, RCEL is priced at $4.54, while IRMD trades at $95.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas IRMD's P/E ratio is 55.88. In terms of profitability, RCEL's ROE is +4.77%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, RCEL is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check IRMD's competition here
RCEL vs CNMD Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, CNMD has a market cap of 1.1B. Regarding current trading prices, RCEL is priced at $4.54, while CNMD trades at $36.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas CNMD's P/E ratio is 24.46. In terms of profitability, RCEL's ROE is +4.77%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, RCEL is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check CNMD's competition here
RCEL vs SILK Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, RCEL is priced at $4.54, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas SILK's P/E ratio is -18.96. In terms of profitability, RCEL's ROE is +4.77%, compared to SILK's ROE of -0.35%. Regarding short-term risk, RCEL is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check SILK's competition here
RCEL vs FNA Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, RCEL is priced at $4.54, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas FNA's P/E ratio is -19.83. In terms of profitability, RCEL's ROE is +4.77%, compared to FNA's ROE of -0.35%. Regarding short-term risk, RCEL is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check FNA's competition here
RCEL vs BFLY Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, BFLY has a market cap of 1.1B. Regarding current trading prices, RCEL is priced at $4.54, while BFLY trades at $4.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas BFLY's P/E ratio is -13.39. In terms of profitability, RCEL's ROE is +4.77%, compared to BFLY's ROE of -0.35%. Regarding short-term risk, RCEL is more volatile compared to BFLY. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check BFLY's competition here
RCEL vs SSII Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, SSII has a market cap of 904.6M. Regarding current trading prices, RCEL is priced at $4.54, while SSII trades at $4.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas SSII's P/E ratio is -75.33. In terms of profitability, RCEL's ROE is +4.77%, compared to SSII's ROE of -0.30%. Regarding short-term risk, RCEL is more volatile compared to SSII. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check SSII's competition here
RCEL vs LMRI Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, LMRI has a market cap of 893.8M. Regarding current trading prices, RCEL is priced at $4.54, while LMRI trades at $9.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas LMRI's P/E ratio is -14.09. In terms of profitability, RCEL's ROE is +4.77%, compared to LMRI's ROE of -0.18%. Regarding short-term risk, RCEL is more volatile compared to LMRI. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check LMRI's competition here
RCEL vs INMD Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, INMD has a market cap of 867.4M. Regarding current trading prices, RCEL is priced at $4.54, while INMD trades at $13.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas INMD's P/E ratio is 9.57. In terms of profitability, RCEL's ROE is +4.77%, compared to INMD's ROE of +0.15%. Regarding short-term risk, RCEL is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check INMD's competition here
RCEL vs CSII Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, RCEL is priced at $4.54, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas CSII's P/E ratio is -20.83. In terms of profitability, RCEL's ROE is +4.77%, compared to CSII's ROE of -0.14%. Regarding short-term risk, RCEL is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check CSII's competition here
RCEL vs IART Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, IART has a market cap of 766.1M. Regarding current trading prices, RCEL is priced at $4.54, while IART trades at $9.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas IART's P/E ratio is -1.46. In terms of profitability, RCEL's ROE is +4.77%, compared to IART's ROE of -0.44%. Regarding short-term risk, RCEL is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check IART's competition here
RCEL vs CRY Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, RCEL is priced at $4.54, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas CRY's P/E ratio is 425.71. In terms of profitability, RCEL's ROE is +4.77%, compared to CRY's ROE of +0.02%. Regarding short-term risk, RCEL is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check CRY's competition here
RCEL vs CBLL Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, CBLL has a market cap of 699M. Regarding current trading prices, RCEL is priced at $4.54, while CBLL trades at $18.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas CBLL's P/E ratio is -12.72. In terms of profitability, RCEL's ROE is +4.77%, compared to CBLL's ROE of -0.32%. Regarding short-term risk, RCEL is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check CBLL's competition here
RCEL vs AVNS Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, AVNS has a market cap of 655.3M. Regarding current trading prices, RCEL is priced at $4.54, while AVNS trades at $14.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas AVNS's P/E ratio is -8.97. In terms of profitability, RCEL's ROE is +4.77%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, RCEL is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check AVNS's competition here
RCEL vs SRDX Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, RCEL is priced at $4.54, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas SRDX's P/E ratio is -34.66. In terms of profitability, RCEL's ROE is +4.77%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, RCEL is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check SRDX's competition here
RCEL vs BVS Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, BVS has a market cap of 613M. Regarding current trading prices, RCEL is priced at $4.54, while BVS trades at $9.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas BVS's P/E ratio is 27.58. In terms of profitability, RCEL's ROE is +4.77%, compared to BVS's ROE of +0.14%. Regarding short-term risk, RCEL is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check BVS's competition here
RCEL vs SIBN Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, SIBN has a market cap of 604.6M. Regarding current trading prices, RCEL is priced at $4.54, while SIBN trades at $13.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas SIBN's P/E ratio is -31.11. In terms of profitability, RCEL's ROE is +4.77%, compared to SIBN's ROE of -0.11%. Regarding short-term risk, RCEL is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check SIBN's competition here
RCEL vs CTKB Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, CTKB has a market cap of 593.9M. Regarding current trading prices, RCEL is priced at $4.54, while CTKB trades at $4.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas CTKB's P/E ratio is -8.88. In terms of profitability, RCEL's ROE is +4.77%, compared to CTKB's ROE of -0.18%. Regarding short-term risk, RCEL is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check CTKB's competition here
RCEL vs APEN Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, RCEL is priced at $4.54, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas APEN's P/E ratio is -9.43. In terms of profitability, RCEL's ROE is +4.77%, compared to APEN's ROE of -0.85%. Regarding short-term risk, RCEL is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check APEN's competition here
RCEL vs BWAY Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, BWAY has a market cap of 560.9M. Regarding current trading prices, RCEL is priced at $4.54, while BWAY trades at $14.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas BWAY's P/E ratio is 79.44. In terms of profitability, RCEL's ROE is +4.77%, compared to BWAY's ROE of +0.11%. Regarding short-term risk, RCEL is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check BWAY's competition here
RCEL vs TCMD Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, TCMD has a market cap of 545.1M. Regarding current trading prices, RCEL is priced at $4.54, while TCMD trades at $23.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas TCMD's P/E ratio is 29.22. In terms of profitability, RCEL's ROE is +4.77%, compared to TCMD's ROE of +0.09%. Regarding short-term risk, RCEL is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check TCMD's competition here
RCEL vs ZIMV Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, RCEL is priced at $4.54, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, RCEL's ROE is +4.77%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, RCEL is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check ZIMV's competition here
RCEL vs OFIX Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, OFIX has a market cap of 498.6M. Regarding current trading prices, RCEL is priced at $4.54, while OFIX trades at $12.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas OFIX's P/E ratio is -5.33. In terms of profitability, RCEL's ROE is +4.77%, compared to OFIX's ROE of -0.20%. Regarding short-term risk, RCEL is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check OFIX's competition here
RCEL vs NPCE Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, NPCE has a market cap of 493.2M. Regarding current trading prices, RCEL is priced at $4.54, while NPCE trades at $14.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas NPCE's P/E ratio is -22.20. In terms of profitability, RCEL's ROE is +4.77%, compared to NPCE's ROE of -1.06%. Regarding short-term risk, RCEL is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check NPCE's competition here
RCEL vs VREX Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, VREX has a market cap of 459.4M. Regarding current trading prices, RCEL is priced at $4.54, while VREX trades at $10.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas VREX's P/E ratio is -6.68. In terms of profitability, RCEL's ROE is +4.77%, compared to VREX's ROE of -0.14%. Regarding short-term risk, RCEL is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check VREX's competition here
RCEL vs PACB Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, PACB has a market cap of 407.7M. Regarding current trading prices, RCEL is priced at $4.54, while PACB trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas PACB's P/E ratio is -0.74. In terms of profitability, RCEL's ROE is +4.77%, compared to PACB's ROE of -11.23%. Regarding short-term risk, RCEL is more volatile compared to PACB. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check PACB's competition here
RCEL vs KIDS Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, KIDS has a market cap of 402.9M. Regarding current trading prices, RCEL is priced at $4.54, while KIDS trades at $15.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas KIDS's P/E ratio is -9.54. In terms of profitability, RCEL's ROE is +4.77%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, RCEL is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check KIDS's competition here
RCEL vs CERS Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, CERS has a market cap of 367M. Regarding current trading prices, RCEL is priced at $4.54, while CERS trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas CERS's P/E ratio is -23.87. In terms of profitability, RCEL's ROE is +4.77%, compared to CERS's ROE of -0.26%. Regarding short-term risk, RCEL is more volatile compared to CERS. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check CERS's competition here
RCEL vs VMD Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, VMD has a market cap of 366.3M. Regarding current trading prices, RCEL is priced at $4.54, while VMD trades at $9.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas VMD's P/E ratio is 25.65. In terms of profitability, RCEL's ROE is +4.77%, compared to VMD's ROE of +0.11%. Regarding short-term risk, RCEL is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check VMD's competition here
RCEL vs LAB Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, LAB has a market cap of 355.4M. Regarding current trading prices, RCEL is priced at $4.54, while LAB trades at $0.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas LAB's P/E ratio is -6.07. In terms of profitability, RCEL's ROE is +4.77%, compared to LAB's ROE of -0.18%. Regarding short-term risk, RCEL is more volatile compared to LAB. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check LAB's competition here
RCEL vs DCTH Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, DCTH has a market cap of 343.3M. Regarding current trading prices, RCEL is priced at $4.54, while DCTH trades at $9.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas DCTH's P/E ratio is 141.14. In terms of profitability, RCEL's ROE is +4.77%, compared to DCTH's ROE of +0.03%. Regarding short-term risk, RCEL is more volatile compared to DCTH. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check DCTH's competition here
RCEL vs CATX Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, CATX has a market cap of 333.7M. Regarding current trading prices, RCEL is priced at $4.54, while CATX trades at $4.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas CATX's P/E ratio is -3.21. In terms of profitability, RCEL's ROE is +4.77%, compared to CATX's ROE of -0.41%. Regarding short-term risk, RCEL is more volatile compared to CATX. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check CATX's competition here
RCEL vs SMLR Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, RCEL is priced at $4.54, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas SMLR's P/E ratio is 3.92. In terms of profitability, RCEL's ROE is +4.77%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, RCEL is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check SMLR's competition here
RCEL vs RXST Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, RXST has a market cap of 279.4M. Regarding current trading prices, RCEL is priced at $4.54, while RXST trades at $6.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas RXST's P/E ratio is -7.13. In terms of profitability, RCEL's ROE is +4.77%, compared to RXST's ROE of -0.14%. Regarding short-term risk, RCEL is more volatile compared to RXST. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check RXST's competition here
RCEL vs SENS Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, SENS has a market cap of 278.6M. Regarding current trading prices, RCEL is priced at $4.54, while SENS trades at $6.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas SENS's P/E ratio is -4.02. In terms of profitability, RCEL's ROE is +4.77%, compared to SENS's ROE of -1.04%. Regarding short-term risk, RCEL is more volatile compared to SENS. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check SENS's competition here
RCEL vs CLPT Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, CLPT has a market cap of 266.5M. Regarding current trading prices, RCEL is priced at $4.54, while CLPT trades at $8.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas CLPT's P/E ratio is -9.96. In terms of profitability, RCEL's ROE is +4.77%, compared to CLPT's ROE of -1.22%. Regarding short-term risk, RCEL is more volatile compared to CLPT. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check CLPT's competition here
RCEL vs MASS Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, MASS has a market cap of 260.2M. Regarding current trading prices, RCEL is priced at $4.54, while MASS trades at $6.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas MASS's P/E ratio is -7.48. In terms of profitability, RCEL's ROE is +4.77%, compared to MASS's ROE of +0.13%. Regarding short-term risk, RCEL is more volatile compared to MASS. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check MASS's competition here
RCEL vs MGRM Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, RCEL is priced at $4.54, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas MGRM's P/E ratio is -11.11. In terms of profitability, RCEL's ROE is +4.77%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, RCEL is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check MGRM's competition here
RCEL vs NVRO Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, RCEL is priced at $4.54, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas NVRO's P/E ratio is -1.91. In terms of profitability, RCEL's ROE is +4.77%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, RCEL is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check NVRO's competition here
RCEL vs ANIK Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, ANIK has a market cap of 219.5M. Regarding current trading prices, RCEL is priced at $4.54, while ANIK trades at $15.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas ANIK's P/E ratio is -21.74. In terms of profitability, RCEL's ROE is +4.77%, compared to ANIK's ROE of -0.07%. Regarding short-term risk, RCEL is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check ANIK's competition here
RCEL vs EYES Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, RCEL is priced at $4.54, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas EYES's P/E ratio is N/A. In terms of profitability, RCEL's ROE is +4.77%, compared to EYES's ROE of -3.17%. Regarding short-term risk, RCEL is more volatile compared to EYES. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check EYES's competition here
RCEL vs ELMD Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, ELMD has a market cap of 203.6M. Regarding current trading prices, RCEL is priced at $4.54, while ELMD trades at $24.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas ELMD's P/E ratio is 23.47. In terms of profitability, RCEL's ROE is +4.77%, compared to ELMD's ROE of +0.20%. Regarding short-term risk, RCEL is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check ELMD's competition here
RCEL vs AVR Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, AVR has a market cap of 202.7M. Regarding current trading prices, RCEL is priced at $4.54, while AVR trades at $5.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas AVR's P/E ratio is -2.16. In terms of profitability, RCEL's ROE is +4.77%, compared to AVR's ROE of -5.28%. Regarding short-term risk, RCEL is more volatile compared to AVR. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check AVR's competition here
RCEL vs CVRX Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, CVRX has a market cap of 196.8M. Regarding current trading prices, RCEL is priced at $4.54, while CVRX trades at $7.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas CVRX's P/E ratio is -3.67. In terms of profitability, RCEL's ROE is +4.77%, compared to CVRX's ROE of -0.99%. Regarding short-term risk, RCEL is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for RCEL.Check CVRX's competition here
RCEL vs PROF Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, PROF has a market cap of 194.9M. Regarding current trading prices, RCEL is priced at $4.54, while PROF trades at $6.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas PROF's P/E ratio is -4.70. In terms of profitability, RCEL's ROE is +4.77%, compared to PROF's ROE of -0.80%. Regarding short-term risk, RCEL is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check PROF's competition here
RCEL vs BSGM Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, RCEL is priced at $4.54, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas BSGM's P/E ratio is -5.81. In terms of profitability, RCEL's ROE is +4.77%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, RCEL is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for RCEL.Check BSGM's competition here
RCEL vs QTI Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, QTI has a market cap of 189.9M. Regarding current trading prices, RCEL is priced at $4.54, while QTI trades at $7.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas QTI's P/E ratio is -3.48. In terms of profitability, RCEL's ROE is +4.77%, compared to QTI's ROE of +3.64%. Regarding short-term risk, RCEL is more volatile compared to QTI. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check QTI's competition here
RCEL vs SGHT Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, SGHT has a market cap of 189M. Regarding current trading prices, RCEL is priced at $4.54, while SGHT trades at $3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas SGHT's P/E ratio is -4.73. In terms of profitability, RCEL's ROE is +4.77%, compared to SGHT's ROE of -0.56%. Regarding short-term risk, RCEL is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check SGHT's competition here
RCEL vs INGN Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, INGN has a market cap of 181.4M. Regarding current trading prices, RCEL is priced at $4.54, while INGN trades at $6.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas INGN's P/E ratio is -7.74. In terms of profitability, RCEL's ROE is +4.77%, compared to INGN's ROE of -0.12%. Regarding short-term risk, RCEL is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check INGN's competition here
RCEL vs MDGS Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, RCEL is priced at $4.54, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas MDGS's P/E ratio is -0.27. In terms of profitability, RCEL's ROE is +4.77%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, RCEL is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for RCEL.Check MDGS's competition here
RCEL vs APYX Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, APYX has a market cap of 167.3M. Regarding current trading prices, RCEL is priced at $4.54, while APYX trades at $4.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas APYX's P/E ratio is -14.81. In terms of profitability, RCEL's ROE is +4.77%, compared to APYX's ROE of -1.18%. Regarding short-term risk, RCEL is more volatile compared to APYX. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check APYX's competition here
RCEL vs QIPT Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, RCEL is priced at $4.54, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas QIPT's P/E ratio is -15.87. In terms of profitability, RCEL's ROE is +4.77%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, RCEL is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check QIPT's competition here
RCEL vs TLSI Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, TLSI has a market cap of 160.4M. Regarding current trading prices, RCEL is priced at $4.54, while TLSI trades at $4.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas TLSI's P/E ratio is -2.30. In terms of profitability, RCEL's ROE is +4.77%, compared to TLSI's ROE of +1.37%. Regarding short-term risk, RCEL is more volatile compared to TLSI. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check TLSI's competition here
RCEL vs SNWV Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, SNWV has a market cap of 156.1M. Regarding current trading prices, RCEL is priced at $4.54, while SNWV trades at $18.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas SNWV's P/E ratio is 44.29. In terms of profitability, RCEL's ROE is +4.77%, compared to SNWV's ROE of -1.42%. Regarding short-term risk, RCEL is more volatile compared to SNWV. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check SNWV's competition here
RCEL vs QTRX Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, QTRX has a market cap of 154.9M. Regarding current trading prices, RCEL is priced at $4.54, while QTRX trades at $3.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas QTRX's P/E ratio is -1.31. In terms of profitability, RCEL's ROE is +4.77%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, RCEL is more volatile compared to QTRX. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check QTRX's competition here
RCEL vs NNOX Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, NNOX has a market cap of 147.9M. Regarding current trading prices, RCEL is priced at $4.54, while NNOX trades at $2.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas NNOX's P/E ratio is -2.64. In terms of profitability, RCEL's ROE is +4.77%, compared to NNOX's ROE of -0.32%. Regarding short-term risk, RCEL is more volatile compared to NNOX. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check NNOX's competition here
RCEL vs EDAP Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, EDAP has a market cap of 125.9M. Regarding current trading prices, RCEL is priced at $4.54, while EDAP trades at $3.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas EDAP's P/E ratio is -4.31. In terms of profitability, RCEL's ROE is +4.77%, compared to EDAP's ROE of -1.12%. Regarding short-term risk, RCEL is more volatile compared to EDAP. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check EDAP's competition here
RCEL vs LUCD Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, LUCD has a market cap of 117.6M. Regarding current trading prices, RCEL is priced at $4.54, while LUCD trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas LUCD's P/E ratio is -1.67. In terms of profitability, RCEL's ROE is +4.77%, compared to LUCD's ROE of -5.91%. Regarding short-term risk, RCEL is more volatile compared to LUCD. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check LUCD's competition here
RCEL vs FONR Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, FONR has a market cap of 114.9M. Regarding current trading prices, RCEL is priced at $4.54, while FONR trades at $18.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas FONR's P/E ratio is 16.18. In terms of profitability, RCEL's ROE is +4.77%, compared to FONR's ROE of +0.04%. Regarding short-term risk, RCEL is more volatile compared to FONR. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check FONR's competition here
RCEL vs ICAD Comparison April 2026
RCEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 112.8M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, RCEL is priced at $4.54, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -2.61, whereas ICAD's P/E ratio is -20.37. In terms of profitability, RCEL's ROE is +4.77%, compared to ICAD's ROE of -0.06%. Regarding short-term risk, RCEL is more volatile compared to ICAD. This indicates potentially higher risk in terms of short-term price fluctuations for RCEL.Check ICAD's competition here